Pharmaceutical News RSS Feed - Pharmaceutical News

EGPAF applauds new licensing agreement to improve access to HIV medication for children

EGPAF applauds new licensing agreement to improve access to HIV medication for children

The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the new licensing agreement between the Medicines Patent Pool (MPP) and Gilead Sciences, Inc. to improve access to tenofovir alafenamide fumarate (TAF), a promising new HIV medication. [More]
Study investigates ventilation strategies used during anaesthesia given for abdomen surgery

Study investigates ventilation strategies used during anaesthesia given for abdomen surgery

A multi-centre study at 30 centres across Europe, North and South America involving a total of 900 test subjects has investigated various ventilation strategies currently used during anaesthesia given for surgical procedures involving the abdomen to see just how effective they are. [More]
XPro1595 drug can protect vulnerable neurons, reduce motor deficits in Parkinson's model

XPro1595 drug can protect vulnerable neurons, reduce motor deficits in Parkinson's model

An experimental anti-inflammatory drug can protect vulnerable neurons and reduce motor deficits in a rat model of Parkinson's disease, researchers at Emory University School of Medicine have shown. [More]
EMA recommends full marketing approval for IMBRUVICA in the European Union

EMA recommends full marketing approval for IMBRUVICA in the European Union

Pharmacyclics, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA (ibrutinib) in the European Union. [More]
Funding for antibiotic research in the UK are inadequate, study reveals

Funding for antibiotic research in the UK are inadequate, study reveals

Less than 1% of research funding awarded by public and charitable bodies to UK researchers in 2008–13 was awarded for research on antibiotics, according to new research published in The Lancet Infectious Diseases. [More]
Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Today Biogen Idec announced that the European Commission (EC) has granted marketing authorization for PLEGRIDY (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). [More]
Genticel provides update on patents granted in the USA and Asia

Genticel provides update on patents granted in the USA and Asia

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, provides an update on patents that have recently enriched its intellectual property estate. [More]
Exposure to light at night renders breast cancer completely resistant to drug

Exposure to light at night renders breast cancer completely resistant to drug

Exposure to light at night, which shuts off nighttime production of the hormone melatonin, renders breast cancer completely resistant to tamoxifen, a widely used breast cancer drug, says a new study by Tulane University School of Medicine cancer researchers. [More]
Researchers working to develop new drugs for treating chronic inflammatory diseases

Researchers working to develop new drugs for treating chronic inflammatory diseases

Science and industry are collaborating to develop future pharmaceuticals for treating chronic inflammatory diseases. The medicines will combat immunological processes that have gone wrong. [More]
New version of drug successfully treats lupus in mice

New version of drug successfully treats lupus in mice

Expanding on his work with a new drug that successfully treated lupus in mice, a biomedical engineer at the University of Houston has received a $250,000 grant to expand his research to a new version of the drug in an effort to treat a wider range of autoimmune diseases. [More]
HPV vaccination may be effective in reducing abnormal Pap test results even after sexual debut

HPV vaccination may be effective in reducing abnormal Pap test results even after sexual debut

Minority women who received the Human Papillomavirus Vaccination (HPV) even after becoming sexually active had lower rates of abnormal Pap test results than those who were never vaccinated. [More]
Researchers uncover how malaria parasite becomes resistant to fosmidomycin drug

Researchers uncover how malaria parasite becomes resistant to fosmidomycin drug

Researchers have uncovered a way the malaria parasite becomes resistant to an investigational drug. The discovery, at Washington University School of Medicine in St. Louis, also is relevant for other infectious diseases including bacterial infections and tuberculosis. [More]
Statins reduce patient's risk of developing Barrett's esophagus

Statins reduce patient's risk of developing Barrett's esophagus

Statins, a class of drugs commonly used to lower cholesterol levels, significantly reduce a patient's risk of developing Barrett's esophagus, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. [More]
FDA approves Targiniq ER to treat severe pain

FDA approves Targiniq ER to treat severe pain

Today, the U.S. Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), an extended-release/long-acting (ER/LA) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. [More]
FDA approves Ryanodex for treatment of malignant hyperthermia linked with anesthesia

FDA approves Ryanodex for treatment of malignant hyperthermia linked with anesthesia

Eagle Pharmaceuticals, Inc. today announced the U. S. Food and Drug Administration (FDA) has approved Ryanodex® (dantrolene sodium) for injectable suspension indicated for the treatment of malignant hyperthermia (MH), along with the appropriate supportive measures. [More]
Capsazepine shows dramatic tumor shrinkage without damaging surrounding tissues

Capsazepine shows dramatic tumor shrinkage without damaging surrounding tissues

Mouse models of human oral cancer treated with an agent called capsazepine showed dramatic tumor shrinkage without damage to surrounding tissues, researchers from the School of Dentistry and School of Medicine at The University of Texas Health Science Center at San Antonio found. [More]
Zydelig gets FDA approval for treatment of patients with three types of blood cancers

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. [More]
Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

Shire plc, the global specialty biopharmaceutical company, and ArmaGen, a US privately held biotechnology company, today announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of both the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome (MPS II). [More]
Sinovac selected to supply seasonal influenza vaccine to Beijing citizens

Sinovac selected to supply seasonal influenza vaccine to Beijing citizens

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention to be a supplier of the seasonal influenza vaccine to the citizens of Beijing for 2014. [More]
Iowa researchers develop vaccine to combat dust-mite allergies

Iowa researchers develop vaccine to combat dust-mite allergies

Researchers at the University of Iowa have developed a vaccine that can combat dust-mite allergies by naturally switching the body's immune response. [More]